In addition to +TIPs, other nonclassical MAPs are being identified. According to recent studies that analyzed microtubules in vivo using cryo-electron tomography, dense material may bind to the inside or become part of microtubule walls (Sui and Downing, 2006; Nicastro et al., 2006; Bouchet-Marquis et al., 2006) . The actual composition of this dense material (which may include new classes of MAPs) and its function are not fully understood. Nonetheless, it is becoming increasingly clear that microtubules provide a variety of diverse interfaces to MAPs. This might be evolutionarily advantageous because a particular mutation of tubulin may favorably change its interaction with one MAP without disturbing its interactions with other MAPs. Microtubules, therefore, may show different "faces" to different MAPs, depending on context and purpose of interaction.
Duchenne muscular dystrophy (DMD) is a devastating X-linked muscle disease resulting from the loss of the large cytoskeletal protein dystrophin. Affected males suffer progressive muscle degeneration and typically die in their late teens or early twenties. No effective treatment is available but some therapeutic interventions are in clinical trials, including viral delivery of dystrophin and exon skipping using antisense oligonucleotides to replace defective dystrophin (Nowak and Davies, 2004) . A useful animal model of DMD is the golden retriever dog model in which a single mutation in intron 6 of the dystrophin gene results in complete absence of the protein and a recapitulation of the severe muscle degeneration and pathology seen in human DMD patients.
Stem cells have attracted much attention as a source of healthy muscle precursor cells that could repopulate dystrophic muscles, replacing defective dystrophin with the wild-type protein. In a recent study, Cossu and colleagues put this to the test delivering a blood-vessel-derived stem cell, called a mesoangioblast, into the bloodstream of golden retriever dystrophic dogs . They report restoration of dystrophin to muscle and improvements in muscle function and mobility There is currently no effective treatment for the devastating muscle-wasting disease Duchenne muscular dystrophy (DMD). Cossu and colleagues report in a recent Nature paper that transplantation of mesoangioblast stem cells may hold promise for treating DMD. Further studies are required to fully evaluate the clinical potential of these bloodvessel-associated stem cells.
Cell 127, December 29, 2006 ©2006 Elsevier Inc. 1305 ologous cells); others received mesoangioblasts that had been removed from the affected dogs (autologous cells) and transduced with a lentiviral vector expressing human microdystrophin, a truncated but functional version of dystrophin. Either heterologous or autologous mesoangioblasts were injected into the femoral artery of adult dystrophic dogs, all of which were maintained on steroids as standard treatment. Dystrophic dogs receiving heterologous mesoangioblasts also received immunosuppressant drugs. The results of the stem cell injections are very encouraging with improvements observed in muscle function and mobility in the dystrophic animals. However, the study does raise several questions, including why dogs that received heterologous cells showed the most improvement and why there is not a stronger correlation between improved muscle function and the amount of dystrophin detected in skeletal muscles of the dystrophic dogs. The use of embryonic or fetalderived stem cells for transplantation purposes raises complex ethical issues, whereas obtaining stem cells from postnatal and adult tissues avoids many of these difficulties. Mesoangioblasts were originally isolated from blood vessels of the dorsal aorta in mouse embryos . In the dog study, the mesoangioblasts were derived from outgrowths of small blood vessels in muscle biopsies taken about 2 weeks after birth. This procedure is similar to that used by Morosetti et al. (2006) in which fragments of intramuscular vessels and surrounding mesenchymal tissue are plated in culture to obtain these cells. Although the mesoangioblasts in the dog study were derived from blood vessels in postnatal muscle, it is difficult to formally exclude the possibility that they might instead be derived from other types of mesenchymal tissue with known myogenic potential, such as mesenchymal stem cells or muscle-derived stem cells (Lee-Pullen and Grounds, 2005) . One way to overcome possible problems of contamination by myogenic stem cells would be to extract the mesoangioblasts from blood vessels derived from nonmuscle tissues (although ubiquitous mesenchymal stem cells exist here too). This issue does not alter the value of dystrophin restoration by implanted mesoangioblasts. However, it will be important to define the precise origin and nature of these myogenic stem cells in humans before they can be used in clinical trials.
The specific contribution of stem cells to the improvements in the DMD dogs relies largely on detecting stem cell-derived dystrophin within skeletal muscles of the treated animals, in particular the leg muscle receiving the injection. The authors present detailed dystrophin analyses for four of the nine test animals (two injected with heterologous mesoangioblasts and two with autologous mesoangioblasts). Although dystrophin expression was increased in many muscles, there was not always a close relationship between the number of dystrophin-positive myofibers and the overall improvements observed . The proposal that replacement of missing dystrophin was a major factor in the improved health of the treated dogs-especially for those that received heterologous cells-requires further substantiation. One reason for the lesser benefits in dogs injected with the genetically corrected autologous cells is that, although human dystrophin is very similar to dog dystrophin, the human microdystrophin introduced into the autologous cells will not function as well as the full-length native protein. Dystrophin analysis in the remaining five treated dogs might help to clarify these issues.
There may be other explanations for the improved strength and gait of skeletal muscles and reduced serum creatine kinase levels (an indicator of improved muscle health) in dogs treated with heterologous mesoangioblasts. The beneficial effects could be the result of the immunosuppressive drugs given to these animals. It is well-documented that anti-inflammatory and immunosuppressive drugs can reduce the severity of muscular dystrophy (Radley et al., 2006) . Early clinical trials with the immunosuppressant drug cyclosporine in DMD patients significantly increased muscle force after 2 months of treatment; a similar effect is also seen with the steroid prednisolone (Sharma et al., 1993) . A long-term study using cyclosporine combined with myoblast therapy to treat DMD patients attributed many of the benefits of increased strength after 7 months to the effects of cyclosporine alone (Miller et al., 1997) . Currently, cyclosporine combined with prednisolone is in clinical trials for treating DMD patients. In the mouse model of DMD (the mdx mouse), cyclosporine increased muscle strength, reduced histological evidence of myofiber damage, and dramatically decreased serum creatine kinase levels, along with other benefits (De Luca et al., 2005) . However, in other situations such as high doses of cyclosporine in young mdx mice, this drug can have adverse effects on dystrophic muscle (Stupka et al., 2004) .
The dosage and impact of the drugs used in this dystrophic dog model need to be carefully assessed. The data suggest that a combined therapy of immunosuppressive drugs and steroids (received by the dogs treated with heterologous cells) might have superior benefits to steroid treatment alone. This is a promising outcome given that there is much interest in such potential combined drug therapies for treating muscular dystrophy in humans. Treatment of control dogs with the same drug combinations but without stem cell injections would provide vital data to evaluate the effects of such drug treatments alone.
The experiments of Cossu and colleagues in an interesting dog model of DMD form a very encouraging basis for exploring future stem cell approaches for treating DMD and other muscle disorders. Additional studies are required to clarify the tantalizing promise of mesoangioblasts for stem cell therapy in DMD patients.
In the late 1800s, Santiago Ramon y Cajal discovered that different classes of neurons can have vastly different axon and dendrite patterns. We now know that these unique axon/dendrite patterns correspond with how a particular neuron fits into a circuit. The underlying molecular events governing axon/dendrite patterning in circuit formation are a major topic of interest. One important principle in the formation of neuronal circuits, which stems from the work of Victor Hamburger and his contemporaries, is that the amount of neuronal innervation a target tissue receives is proportional to the amount of survival factors it secretes (Cowan, 2001) . Since this revelation over 50 years ago, we now realize that target-derived growth factors influence survival, axon elaboration, branching, dendrite growth, circuit assembly, and acquisition of neurotransmitter phenotype (Frank and Wenner, 1993; Glebova and Ginty, 2005; Howe and Mobley, 2005) . However, the molecular mechanisms by which target-derived factors and retrograde signaling regulate these processes remain poorly defined. In this issue, Vrieseling and Arber (2006) provide exciting new molecular insights into how a target-derived growth factor controls neural circuit formation in the developing spinal cord.
Sensory neurons of the dorsal root ganglia are unique in that they have an axon with two major branches, one of which projects to the periphery while the other projects into the spinal cord. Sensory neurons of the dorsal root ganglia that monitor the position of the body in space are referred to as proprioceptive neurons. In a well-defined neural circuit that controls the proprioceptive reflex, the central branches of proprioceptive sensory axons connect either directly (making one synaptic connection: monosynaptic) or indirectly (making two or more connections through interneurons: polysynaptic) with dendrites of motor neurons that innervate different muscle groups (Chen et al., 2003) . Although anatomical and physiological characteristics of these reflex circuits have been defined, the molecular and genetic determinants that specify the formation of circuit architecture remain unknown.
At the outset of their study, the authors inject retrograde tracers into various skeletal muscle groups and examine the patterns of dendrites of the corresponding motor neurons in the cervical spinal cord. Although motor neurons innervating the triceps brachii, pectoralis major, and biceps
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